

Astellas Pharma
"Global pharmaceutical company pioneering transformative therapies for patients with serious diseases"
About Astellas Pharma
Astellas develops transformative therapies in oncology, ophthalmology, urology, immunology and women's health. Operating across more than 70 countries, the company invests 17.1% of sales revenue into research addressing disease areas with high unmet need. From drug discovery to commercialisation, Astellas manages the full lifecycle of medicines to improve patient outcomes worldwide. The approach combines pioneering science with patient centricity and collaboration. With more than 13,500 employees, Astellas pursues breakthrough therapies through cell and gene therapy, targeted drug development and digital health solutions. Guided by Integrity, Innovation and Impact, the company creates lasting change in treating serious diseases.


13643
Team Members
2005
Founded
Public
Funding
Hybrid
Work Environment
A world where innovative science transforms healthcare, enabling every patient facing serious disease to access breakthrough therapies that extend life, restore function and improve wellbeing across all communities globally.
Astellas exists to turn innovative science into VALUE for patients through transformative therapies, compassionate care and a commitment to better health outcomes for people facing serious diseases worldwide.